ALKEM:NSE-Alkem Laboratories Limited (INR)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSE

Last Closing Price

INR 3,892.70

Change

0.00 (0.00)%

Market Cap

INR 465.43B

Volume

0.08M

Avg Analyst Target

INR 3,770.00 (-3.15%)

Avg User Target

INR
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Alkem Laboratories Limited, a pharmaceutical company, develops, manufactures, and sells pharmaceutical and nutraceutical products in India and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, dermatology, diabetology, cardiology, gastroenterology, osteoporosis, central nervous system, oncology, urology, and gynaecology, as well as vitamins, minerals, and nutrients; and pain relief/analgesic, anti-diabetic, and neurology products. It also provides pregnancy detection kits and condoms. Alkem Laboratories Limited was incorporated in 1973 and is headquartered in Mumbai, India. Address: Devashish Building, Mumbai, India, 400013

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-17 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

N/A

INR2,018.56B 33.66 21.56
DIVISLAB:NSE Divi's Laboratories Limited

N/A

INR1,426.14B 69.59 43.47
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

N/A

INR822.65B 48.08 21.18
PEL:NSE Piramal Enterprises Limited

N/A

INR677.04B 49.31 11.87
CADILAHC:NSE Cadila Healthcare Limited

N/A

INR557.12B 24.56 17.94
LUPIN:NSE Lupin Limited

N/A

INR429.72B 26.09 14.15
AUROPHARMA:NSE Aurobindo Pharma Limited

N/A

INR426.07B 8.00 5.01
LAURUSLABS:NSE Laurus Labs Limited

N/A

INR349.33B 33.32 21.30
IPCALAB:NSE Ipca Laboratories Limited

N/A

INR307.26B 30.68 20.49
AJANTPHARM:NSE Ajanta Pharma Limited

N/A

INR191.72B 28.32 18.81

ETFs Containing ALKEM

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 31.92% 52% F 37% F
Dividend Return 1.02% 68% D+ 50% F
Total Return 32.94% 52% F 38% F
Trailing 12 Months  
Capital Gain 46.86% 49% F 26% F
Dividend Return 1.13% 72% C- 42% F
Total Return 48.00% 49% F 26% F
Trailing 5 Years  
Capital Gain 122.76% 70% C- 74% C
Dividend Return 4.41% 85% B 53% F
Total Return 127.16% 70% C- 74% C
Average Annual (5 Year Horizon)  
Capital Gain 16.05% 46% F 58% F
Dividend Return 0.70% 77% C+ 50% F
Total Return 16.74% 45% F 58% F
Risk Return Profile  
Volatility (Standard Deviation) 21.81% 97% A+ 93% A
Risk Adjusted Return 76.78% 89% B+ 93% A
Market Capitalization 465.43B 93% A 94% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 28.54 44% F 40% F
Price/Book Ratio 6.38 29% F 18% F
Price / Cash Flow Ratio 36.80 24% F 16% F
EV/EBITDA 21.09 36% F 33% F
Management Effectiveness  
Return on Equity 23.33% 74% C 88% B+
Return on Invested Capital 17.17% 70% C- 86% B
Return on Assets 9.75% 70% C- 86% B
Debt to Equity Ratio 0.46% 67% D+ 80% B-
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.26 86% B 93% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.